These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 22236796

  • 1. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).
    Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, Slack M.
    Eur Urol; 2012 Sep; 62(3):507-14. PubMed ID: 22236796
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates.
    Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A.
    Eur Urol; 2012 Apr; 61(4):834-9. PubMed ID: 22204745
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin A injection for idiopathic detrusor overactivity.
    Kuo HC.
    Neurourol Urodyn; 2011 Nov; 30(8):1497-502. PubMed ID: 21717501
    [Abstract] [Full Text] [Related]

  • 12. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.
    Peyronnet B, Roumiguié M, Castel-Lacanal E, Guillotreau J, Malavaud B, Marque P, Rischmann P, Gamé X.
    Neurourol Urodyn; 2016 Feb; 35(2):267-70. PubMed ID: 25524826
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF, Chiu HC, Chen KC, Chang CH, Chou EC.
    Toxins (Basel); 2016 Feb 29; 8(3):. PubMed ID: 26938559
    [Abstract] [Full Text] [Related]

  • 18. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
    Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C, EMBARK Study Group.
    J Urol; 2017 Feb 29; 197(2S):S216-S223. PubMed ID: 28012773
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.